Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

224 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Oncogene- and drug resistance-associated alternative exon usage in acute myeloid leukemia (AML).
Mohamed AM, Balsat M, Thenoz M, Koering C, Payen-Gay L, Cheok M, Mortada H, Auboeuf D, Pinatel C, El-Hamri M, Dumontet C, Cros E, Flandrin-Gresta P, Nibourel O, Preudhomme C, Michallet M, Thomas X, Nicolini F, Solly F, Guyotat D, Campos L, Wattel E, Mortreux F. Mohamed AM, et al. Among authors: guyotat d. Oncotarget. 2016 Jan 19;7(3):2889-909. doi: 10.18632/oncotarget.3898. Oncotarget. 2016. PMID: 26284582 Free PMC article.
TET2 exon 2 skipping is an independent favorable prognostic factor for cytogenetically normal acute myelogenous leukemia (AML): TET2 exon 2 skipping in AML.
Mohamed AM, Balsat M, Koering C, Maucort-Boulch D, Boissel N, Payen-Gay L, Cheok M, Mortada H, Auboeuf D, Pinatel C, El-Hamri M, Tigaud I, Hayette S, Dumontet C, Cros E, Flandrin-Gresta P, Nibourel O, Preudhomme C, Thomas X, Nicolini FE, Solly F, Guyotat D, Campos L, Michallet M, Ceraulo A, Mortreux F, Wattel E. Mohamed AM, et al. Among authors: guyotat d. Leuk Res. 2017 May;56:21-28. doi: 10.1016/j.leukres.2017.01.012. Epub 2017 Jan 16. Leuk Res. 2017. PMID: 28167452
An miRNA-DNMT1 Axis Is Involved in Azacitidine Resistance and Predicts Survival in Higher-Risk Myelodysplastic Syndrome and Low Blast Count Acute Myeloid Leukemia.
Solly F, Koering C, Mohamed AM, Maucort-Boulch D, Robert G, Auberger P, Flandrin-Gresta P, Adès L, Fenaux P, Kosmider O, Tavernier-Tardy E, Cornillon J, Guyotat D, Campos L, Mortreux F, Wattel E. Solly F, et al. Among authors: guyotat d. Clin Cancer Res. 2017 Jun 15;23(12):3025-3034. doi: 10.1158/1078-0432.CCR-16-2304. Epub 2016 Nov 23. Clin Cancer Res. 2017. PMID: 27881579
Expression of embryonic stem cell markers in acute myeloid leukemia.
Picot T, Aanei CM, Fayard A, Flandrin-Gresta P, Tondeur S, Gouttenoire M, Tavernier-Tardy E, Wattel E, Guyotat D, Campos L. Picot T, et al. Among authors: guyotat d. Tumour Biol. 2017 Jul;39(7):1010428317716629. doi: 10.1177/1010428317716629. Tumour Biol. 2017. PMID: 28718379 Free article.
Influence of major BCR-ABL1 transcript subtype on outcome in patients with chronic myeloid leukemia in chronic phase treated frontline with nilotinib.
Genthon A, Nicolini FE, Huguet F, Colin-Gil C, Berger M, Saugues S, Janel A, Hayette S, Cohny-Makhoul P, Cadoux N, Cayuela JM, Campos L, Guyotat D, Flandrin-Gresta P. Genthon A, et al. Among authors: guyotat d. Oncotarget. 2020 Jun 30;11(26):2560-2570. doi: 10.18632/oncotarget.27652. eCollection 2020 Jun 30. Oncotarget. 2020. PMID: 32655840 Free PMC article.
Potential Role of OCT4 in Leukemogenesis.
Picot T, Kesr S, Wu Y, Aanei CM, Flandrin-Gresta P, Tondeur S, Tavernier E, Wattel E, Guyotat D, Campos L. Picot T, et al. Among authors: guyotat d. Stem Cells Dev. 2017 Nov 15;26(22):1637-1647. doi: 10.1089/scd.2017.0134. Epub 2017 Oct 16. Stem Cells Dev. 2017. PMID: 28911263
Heat shock proteins and acute leukemias.
Thomas X, Campos L, Le QH, Guyotat D. Thomas X, et al. Among authors: guyotat d. Hematology. 2005 Jun;10(3):225-35. doi: 10.1080/10245330500093120. Hematology. 2005. PMID: 16019471 Free article. Review.
224 results